Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report

Hu, Linjun; Shan, Xingli; Han, Dongdong; Zhaoxia, Guo; Wang, Huina; Xiao, Zhijian

doi:10.2147/ott.s319932

Cited by 6 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, they did not compare the efficacy difference between subgroups of PD-L1 high and low, as researchers did in other types of tumors. Under the light of clinical trials, a few case series and case reports were published, promoting the application of immunotherapy in penile carcinoma and indicating the crucial role of PD-L1 expression in immunotherapy ( 32 – 35 ). Unfortunately, there were few studies in this area, and more well-designed studies are warranted.…”

Section: Discussionmentioning

confidence: 99%

PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis

Lü

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundPrevious studies have explored the role of PD-L1 in the survival outcomes of penile cancer patients with controversies existed. Thus, the meta-analysis was conducted to report and review the association between PD-L1 and survival in penile cancer patients.MethodsPubMed, Cochrane Library, EMBASE, and Web of Science were all searched, screened, and reviewed by June 1, 2022. Hazard ratio (HR) was used to evaluate the relationship between PD-L1 and survival outcome, and odds ratio (OR) was for tumor features.ResultsNine retrospective studies (1,003 patients) were incorporated. The prevalence of PD-L1 in patients with penile cancer was 51.4% (95% CI = 42.1%-60.8%, I2 = 88.5%). Higher PD-L1 on tumor cells was related to shorter cancer-specific survival (CSS) in patients (HR = 1.578, 95% CI = 1.227-2.029, I2 = 23.3%), but had no associations with overall survival (OS) (HR = 1.123, 95% CI = 0.511-2.465, I2 = 0.0%). Subgroup analysis indicated that higher PD-L1 was related to shorter CSS in Caucasus (HR = 1.827, 95% CI = 1.355-2.465, I2 = 0.0%) only. Furthermore, PD-L1 had associations with tumor stage (pT1 vs. pT2-4, OR = 0.480, 95% CI = 0.346-0.667, P = 0.001) and tumor grade (Well and moderate vs. Poor, OR = 0.377, 95% CI = 0.264-0.538, P < 0.001). PD-L1 positivity was also related to lymph node (LN) status (pN0/NX vs. pN1–3, OR = 0.541, 95% CI = 0.385-0.759, P = 0.001) and HPV status (Positive vs. Negative, OR = 0.510, 95% CI = 0.322-0.810, P = 0.003). A trend toward statistical significance between PD-L1 and histological types was also observed (Usual SCC vs. Others, OR = 1.754, 95% CI = 0.984-3.124, P = 0.070).ConclusionsPD-L1 over-expression was related to worse survival outcomes and several clinicopathological features of penile cancer. PD-L1 expression can be applied to select appropriate treatment strategies for penile malignancies.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=343041, identifier CRD42022343041.

show abstract

Section: Discussionmentioning

confidence: 99%

PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis

Lü

Wang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Comfortingly, most of the patients in these case reports presented with a partial response or a near-complete response. Hu et al [ 18 ] reported a recurrent PSCC patient with medium PD-L1 expression and low TMB who obtained complete response after multimodal therapy that included surgical resection, adjuvant chemotherapy, and continuous sintilimab. It was also recently reported that immunotherapy combined with chemotherapy could have good therapeutic effects in advanced PSCC patients [ 19 , 20 ].…”

Section: Discussionmentioning

confidence: 99%

Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review

Zhang

et al. 2022

Current Oncology

View full text Add to dashboard Cite

Penile squamous cell carcinoma (PSCC) is a rare disease. The treatment options for advanced penile cancer are often limited, and the prognosis remains poor. We reported a 52-year-old male recurrent and metastatic PSCC patient with high PD-L1 expression (90%) and TMB (14.4 muts/Mb). He had undergone penectomy, bilateral inguinal lymph node dissection, and excision of the abdominal wall mass. Despite cisplatin-based concurrent chemoradiotherapy and sequential chemotherapy with docetaxel plus cisplatin then being carried out, the carcinoma still progressed. The patient then obtained progression-free survival with continuous sintilimab, although he experienced the new onset of ICI-induced diabetes after 24 cycles of sintilimab and required sustained insulin treatment. He had negative type 1 diabetes-associated autoantibodies and the susceptible HLA genotype DR3-DQ2 haplotype. This is the first patient with radiation and multichemorefractory PSCC who has obtained the remarkable anti-tumor effect of partial regression exceeding 32 months during continuous sintilimab and anlotinib treatment.

show abstract

“…In China, Su et al [15]reported a recurrent metastatic penile SCC patient with positive PD-L1 expression (≥10%) and high TMB of 8.87 (Muts/Mb) who obtained significant response to toripalimab, with progression free survival exceeding 10 months. Hu et al [16]reported a 49-year-old recurrent penile SCC patient with medium PD-L1 expression and low TMB obtained complete response after multimodal therapy, including resection of palliative right inguinal metastases, four cycles of paclitaxel+bleo-mycin+cisplatin and continuous sintilimab. However, it was also recently reported that immunotherapy combined with chemotherapy had good therapeutic effect in advanced penile SCC patients [17,18].…”

Section: Discussionmentioning

confidence: 99%

Sintilimab-Induced Diabetic Ketoacidosis in A Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review

Lv¹,

Wu²,

Zhang³

et al. 2022

Preprint

View full text Add to dashboard Cite

Penile squamous cell carcinoma (SCC) is a rare disease. Treatment options for advanced penile cancer are often limited and prognosis remains poor. We reported a 52-year-old male recurrent and metastatic penile SCC patient with high PD-L1 expression(90%) and TMB(14.4 muts/Mb). He had undergone penectomy, bilateral inguinal lymph node dissection and excision of the abdominal wall mass during two surgeries. Despite cisplatin-based concurrent chemoradiotherapy and sequential chemotherapy with docetaxel plus cisplatin were then carried out, the carcinoma still had progressed. The patient then obtained progression free survival exceeding 32 months with continuous sintilimab, although new onset of ICI-induced diabetes after 24 cycles of sintilimab and required sustained insulin treatment. He didn’t have positive type 1 diabetes associated autoantibodies, but had susceptible HLA genotype DR3-DQ2 haplotype. This is the first patient with radiation and multichemorefractory penile SCC obtained remarkable anti-tumor effect of partial regression exceeding 32 months during continuous sintilimab.

show abstract

Multimodal Treatment Combining Salvage Surgery-Assisted Chemotherapy and Checkpoints Blockade Immunotherapy Achieves Complete Remission on a Recurrent Penile Cancer Patient: A Case Report

Cited by 6 publications

References 29 publications

PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis

PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis

Sintilimab-Induced Diabetic Ketoacidosis in a Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review

Sintilimab-Induced Diabetic Ketoacidosis in A Patient with Radiation and Multichemorefractory Penile Cancer: A Case Report and Literature Review

Contact Info

Product

Resources

About